With Access Restricted, Aduhelm Appears Poised For A Slow Start
Payers Speak Out At ICER Public Meeting
Reimbursement, health policy and medical experts predicted a slow rollout ahead for Biogen's new Alzheimer's treatment at a public meeting sponsored by ICER.
You may also be interested in...
Scrip and Pink Sheet editors join Datamonitor Healthcare analysts to discuss Biogen's Aduhelm for Alzheimer's disease, including the expected launch trajectory, early commercial barriers to uptake and the Medicare reimbursement environment.
Management tried to sidestep controversy around the approval of Aduhelm and said it remains confident the drug will be reimbursed.
Woodcock again defends the decision, saying Congress intended accelerated approval for those situations.